M&A Deal Summary |
|
|---|---|
| Date | 2021-11-22 |
| Target | Laboratoris Sanifit |
| Sector | Life Science |
| Buyer(s) | Vifor Pharma Group |
| Sellers(s) | Gilde Healthcare |
| Deal Type | Add-on Acquisition |
| Deal Value | 205M EUR |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1972 |
| Sector | Life Science |
| Employees | 2,384 |
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group was founded in 1972 and is based in Glattbrugg, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector (Life Science) | 2 of 2 |
| Type (Add-on Acquisition) | 2 of 2 |
| Country (Spain) | 1 of 1 |
| Year (2021) | 2 of 2 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-11-22 |
Inositec
Zurich, Switzerland Inositec is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune platform of inositol phosphate (IP6) analogs. The company’s lead programs address vascular and renal calcification disorders, including orphan indications. Inositec’s novel asset INS-3001, is a once-daily subcutaneous treatment for patients with vascular calcification disorders PAD and AVS, which are both major contributors to cardiovascular morbidity and mortality in affected patient populations. With INS-3001 daily subcutaneous dosing, patients with earlier stages of vascular calcification can be optimally treated, while end-stage kidney disease patients will benefit from the three times per week dosing regimen of SNF472. Inositec was formed in 2015 and is based in Zurich, Switzerland. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1999 |
| PE ASSETS | 800M EUR |
| Size | Middle-Market |
| Type | Sector Focused |
Gilde Healthcare is a specialist private equity and venture investor focused on the healthcare sector. The Firm's buyout group targets majority investments throughout Europe (preference for Germany, the Netherlands, Belgium, Austria or Switzerland) and has a focus on healthcare providers, suppliers and service providers active in the healthcare market. The Firm's venture group looks to invest up to €30 million in early stage medtech, diagnostics, digital health and therapeutics companies throughout North America and Europe. Gilde Healthcare was established in 2001 and is headquartered in Utrecht, the Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 28 of 30 |
| Sector (Life Science) | 16 of 16 |
| Type (Add-on Acquisition) | 14 of 15 |
| Country (Spain) | 2 of 2 |
| Year (2021) | 2 of 3 |
| Size (of disclosed) | 3 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-25 |
Symeres
Nijmegen, Netherlands Symeres is a mid-sized European Contract Research Organization for drug discovery and development needs. The company offers best-in-class solutions for drug discovery and drug development for small molecules and beyond. Their services span from preclinical hit finding all the way to the delivery of early clinical phase drug substance API. Symeres blends a deep scientific knowledge base with creativity and problem-solving skills to deliver the quality results that clients need. Symeres is based in Nijmegen, Netherlands. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-12-03 |
DETAX
Ettlingen, Germany DETAX is a specialist in polymer materials, the group offers its customers a comprehensive product portfolio of dental and otoplastic consumables. The group serves an international, broadly diversified, and loyal customer base. End-users of the products include dental practices, dental laboratories as well as audiologists, and audio laboratories. DETAX was founded in 1953 and is based in Ettlingen, Germany. |
Buy | - |
